H.R. 2873 117th Congress
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
- Commerce
- Sponsor: Rep. Cicilline, David N. [D-RI-1]
- Congress.gov ↗
Latest action, Sep 29, 2021: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 27 - 16.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
5 cosponsors
Sponsored by Rep. Cicilline, David N. [D-RI-1] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
4 D · 1 R
Referred to: House: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
7 reports
7 reports
JOHNSON & JOHNSON SERVICES, INC.
BROWNSTEIN HYATT FARBER SCHRECK, LLP
7 reports
7 reports
7 reports
PHRMA
NVG, LLC
7 reports
6 reports
6 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
THE GIBSON GROUP, LLC
6 reports
CONSERVATIVES FOR PROPERTY RIGHTS
JAMES EDWARDS
6 reports
All 25 of 43 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ASTRAZENECA PHARMACEUTICALS LP | 7 | $8.2M | Q4 2021 | Q3 2022 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | $23.5M | Q4 2021 | Q3 2022 | yes | |
| CHAMBER OF COMMERCE OF THE U.S.A. | 7 | $127.0M | Q4 2021 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.0M | Q4 2021 | Q3 2022 | yes | |
| JOHNSON & JOHNSON SERVICES, INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| MERCK & CO INC | 7 | $12.7M | Q4 2021 | Q3 2022 | yes | |
| NOVARTIS | 7 | $10.1M | Q4 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 7 | $14.1M | Q4 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $49.3M | Q4 2021 | Q3 2022 | yes | |
| PHRMA | NVG, LLC | 7 | $420K | Q4 2021 | Q3 2022 | yes |
| ABBVIE INC. | 6 | $11.4M | Q4 2021 | Q3 2022 | yes | |
| AMGEN INC | 6 | $15.2M | Q4 2021 | Q3 2022 | yes | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | THE GIBSON GROUP, LLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| CONSERVATIVES FOR PROPERTY RIGHTS | JAMES EDWARDS | 6 | $180K | Q4 2021 | Q3 2022 | yes |
| CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 6 | $954K | Q4 2021 | Q3 2022 | yes | |
| ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| ELI LILLY AND COMPANY | 6 | $10.3M | Q4 2021 | Q3 2022 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 6 | $313K | Q4 2021 | Q3 2022 | yes | |
| NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| PFIZER | WILLIAMS AND JENSEN, PLLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| PHRMA | WILLIAMS AND JENSEN, PLLC | 6 | $300K | Q4 2021 | Q3 2022 | yes |
| REGENXBIO | 6 | $507K | Q4 2021 | Q3 2022 | yes | |
| TEVA PHARMACEUTICALS USA INC | 6 | $5.3M | Q4 2021 | Q3 2022 | yes | |
| TRAVERE THERAPEUTICS | 6 | $1.0M | Q4 2021 | Q3 2022 | yes | |
| GENENTECH INC | 5 | $10.0M | Q4 2021 | Q3 2022 | yes |